Medesis Pharma SA
PAR:ALMDP

Watchlist Manager
Medesis Pharma SA Logo
Medesis Pharma SA
PAR:ALMDP
Watchlist
Price: 0.35 EUR
Market Cap: 1.8m EUR

Medesis Pharma SA
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Medesis Pharma SA
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Medesis Pharma SA
PAR:ALMDP
Operating Income
-€3.2m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Technip Energies NV
PAR:TE
Operating Income
€460.4m
CAGR 3-Years
-8%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
V
Vallourec SA
PAR:VK
Operating Income
€878m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
Altareit SCA
PAR:AREIT
Operating Income
€20.4m
CAGR 3-Years
-49%
CAGR 5-Years
-31%
CAGR 10-Years
-10%
F
Frey SA
PAR:FREY
Operating Income
€102.1m
CAGR 3-Years
27%
CAGR 5-Years
26%
CAGR 10-Years
25%
Galimmo SCA
PAR:GALIM
Operating Income
€34m
CAGR 3-Years
19%
CAGR 5-Years
4%
CAGR 10-Years
N/A
No Stocks Found

Medesis Pharma SA
Glance View

Market Cap
1.8m EUR
Industry
N/A

Medesis Pharma SA operates as a clinical development stage biopharmaceutical company. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.

ALMDP Intrinsic Value
Not Available

See Also

What is Medesis Pharma SA's Operating Income?
Operating Income
-3.2m EUR

Based on the financial report for Dec 31, 2021, Medesis Pharma SA's Operating Income amounts to -3.2m EUR.

What is Medesis Pharma SA's Operating Income growth rate?
Operating Income CAGR 3Y
-39%

Over the last year, the Operating Income growth was -225%. The average annual Operating Income growth rates for Medesis Pharma SA have been -39% over the past three years .

Back to Top